ClinicalTrials.gg
RecruitingNCT06084832SmartBingeUpdated May 25, 2025

Smartphone Application for University Students With Binge Drinking Behavior

An interventional study of blood microsampling in Alcohol Drinking and Binge Drinking, sponsored by Centre Hospitalier Universitaire, Amiens. Recruiting at 1 site in France. Open to participants aged 18 Years to 25 Years. Per ClinicalTrials.gov, last updated 2025-05-25.

Primary conditionBinge DrinkingRegistry: Alcohol DrinkingReclassifiedWhy we changed it
Registry
Alcohol Drinking — the first condition term the registry derived for this study.
ClinicalTrials.gg
Binge Drinking
Why
  1. Alcohol Drinking is a broad heading, used only when no more specific condition is named.
  2. The study's listed conditions name Binge Drinking, a narrower term within Alcohol Drinking.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Centre Hospitalier Universitaire, Amiens · Not applicable, Interventional, and Prevention

From the registry’s dates

  • Primary completion was expected by Apr 2026, 7 months ago, but the record still lists the study as recruiting.
  • Started Oct 2023; still recruiting 3 years 1 month later.
Phase
Not applicable
Study type
Interventional
Enrollment
628
Allocation
Non-randomized
Ages
18 Years to 25 Years
Sex
All
01

Study summary

Alcohol use is a causal factor in more than 200 diseases and injury conditions (see ICD-10) and in France, alcohol is the first cause of hospitalization. Binge drinking (BD) has emerged as a major public health issue among student populations and is associated with negative consequences and social, cognitive and brain alterations. More than half of French university students have reported BD in the past month and are at increased risk of several alcohol-related consequences such as memory and sleep impairments, and reduced quality of life. BD is also a major risk factor in the development of alcohol addiction, with individual and environmental factors playing a role that is still poorly understood. Moreover, most students and young adults are reluctant to seek interventions when it is provided by health care professionals (only 4-5%) and have poor insight with regard to their alcohol use patterns / habits. Thus, there is an urgent need for developing effective prevention and intervention programs to reduce alcohol drinking in students. Recent studies have demonstrated that new types of technology-delivered interventions are promising tools for addressing unhealthy alcohol use. For example, an uncontrolled trial pilot study using a smartphone application-delivered intervention produced a reduction in both number of drinks per week and BD from baseline to 3-month follow-up. A recent review also showed significant outcomes of a mobile health intervention for self-control of unhealthy alcohol use. The investigators hypothesize that a timeline follow-back and personalized feedback based on the use of a mobile application can reduce excessive alcohol intake at 3-months. This study will provide scientific knowledge about BD in students, but also regarding a new type of intervention that could be effective for prevention in non-treatment seeking individuals and reducing the severity of health problems associated with excessive alcohol intake.

02

Conditions studied

  • Alcohol Drinking
  • Binge Drinking

Browse trials for

Keywords

  • Alcohol
  • Binge Drinking
  • Phosphatidylethanol
  • Smartphone
  • Health
03

In context

Binge Drinking Reclassified

71 studies on the registry are indexed under Binge Drinking; 20 are open to participants now.

This study's planned enrollment of 628 is above the median of 120 across 64 interventional studies indexed under Binge Drinking.

Browse Binge Drinking studies →

Lead sponsor

Centre Hospitalier Universitaire, Amiens is the lead sponsor of 586 studies on the registry; 185 are open to participants now.

Compared within Binge Drinking, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Alcohol Drinking. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years to 25 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Students between 18 and 25 years old
  • AUQ score greater than or equal to 24, and AUDIT score greater than or equal to 3 for its first 3 items. Drinking details with the DDQ when necessary.
  • BD behavior: at least one occasion with 6 or more drinks in the last 3 months.
  • Consent to be included in the study
  • Affiliated to social security

Exclusion criteria

Exclusion Criteria:

  • Not having a smartphone with an Apple or Android system.
  • Previous use of the MyDéfi smartphone application
  • Declaration of a psychiatric / neurologic condition
  • Pregnant, parturient or breastfeeding woman
  • Subject under guardianship, curators or restricted under public law
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
628 participants (estimated)

Study arms

  • Experimental
    Binge Drinking

    Biological: blood microsampling

  • Active comparator
    Binge Drinking-control

    Biological: blood microsampling

Interventions

  • Biologicalblood microsampling

    blood microsampling for the measure of Phosphatidylethanol

06

What researchers measure

Primary outcomes

  1. Change of the number of standard drinks per week

    Time frame: 30 months

Secondary outcomes

  1. Change of the PEth concentration

    phosphatidylethanol (PEth)

    Time frame: 3 months

  2. Change of the PEth concentration

    phosphatidylethanol (PEth)

    Time frame: 6 months

  3. Change of the PEth concentration

    phosphatidylethanol (PEth)

    Time frame: 9 months

  4. Change of the PEth concentration

    phosphatidylethanol (PEth)

    Time frame: 12 months

  5. Change of the PEth concentration

    phosphatidylethanol (PEth)

    Time frame: 15 months

  6. Change of the PEth concentration

    phosphatidylethanol (PEth)

    Time frame: 18 months

  7. Change of the PEth concentration

    phosphatidylethanol (PEth)

    Time frame: 21 months

  8. Change of the PEth concentration

    phosphatidylethanol (PEth)

    Time frame: 24 months

  9. Change of the PEth concentration

    phosphatidylethanol (PEth)

    Time frame: 27 months

  10. Change of the PEth concentration

    phosphatidylethanol (PEth)

    Time frame: 30 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06084832
Collaborators
EPSM Marne, Reims, SCA-LAB UMR-CNRS 9193, Lille, Paul Valery University, Montpellier
Responsible party
Sponsor
First posted
Oct 16, 2023
Start date
Oct 1, 2023
Primary completion
Apr 2026 (estimated)
Completion
Jul 2026 (estimated)
Last update
May 25, 2025

Study contacts

Mickael Naasila, Pr
Contact
mickael.naassila@u-picardie.fr
03.22.82.76.72
Sandra Bodeau, Dr
Contact
bodeau.sandra@chu-amiens.fr
03.22.08.70.34

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion